Product Code: TMRGL1666
The report provides revenue of the global meningococcal vaccines market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global meningococcal vaccines market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the meningococcal vaccines market.
The report delves into the competitive landscape of the global meningococcal vaccines market. Key players operating in the global meningococcal vaccines market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global meningococcal vaccines market profiled in this report.
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Meningococcal Vaccines Market
4. Market Overview
- 4.1. Introduction
- 4.1.1. Definition
- 4.1.2. Industry Evolution / Developments
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Meningococcal Vaccines Market Analysis and Forecast, 2021-2031
5. Key Insights
- 5.1. Pipeline Analysis
- 5.2. Regulatory Scenario by Region/globally
- 5.3. Covid-19 Impact analysis
6. Global Meningococcal Vaccines Market Analysis and Forecast, by Type
- 6.1. Introduction & Definition
- 6.2. Key Findings / Developments
- 6.3. Global Meningococcal Vaccines Market Value Forecast, by Type, 2021-2031
- 6.3.1. Polysaccharide
- 6.3.1.1. Menomune
- 6.3.1.2. Mencevax
- 6.3.1.3. NmVac4
- 6.3.1.4. Others
- 6.3.2. Conjugate Vaccines
- 6.3.2.1. Menactra
- 6.3.2.2. Menveo
- 6.3.2.3. NeisVac-C
- 6.3.2.4. Nimenrix
- 6.3.2.5. Others
- 6.3.3. Combination Vaccines
- 6.3.3.1. MenHibrix
- 6.3.3.2. Menitorix
- 6.3.4. Men B Vaccines
- 6.3.4.1. Bexsero
- 6.3.4.2. Trumenba
- 6.4. Global Meningococcal Vaccines Market Attractiveness, by Type
7. Global Meningococcal Vaccines Market Analysis and Forecast, by End-user
- 7.1. Introduction & Definition
- 7.2. Key Findings / Developments
- 7.3. Global Meningococcal Vaccines Market Value Forecast, by End-user, 2021-2031
- 7.3.1. Retail Pharmacies
- 7.3.2. Hospital Pharmacies
- 7.3.3. Others (online pharmacies, drug stores)
- 7.4. Global Meningococcal Vaccines Market Attractiveness, by End-user
8. Global Meningococcal Vaccines Market Analysis and Forecast, by Region
- 8.1. Key Findings
- 8.2. Global Meningococcal Vaccines Market Value Forecast, by Region
- 8.2.1. North America
- 8.2.2. Europe
- 8.2.3. Asia Pacific
- 8.2.4. Latin America
- 8.2.5. Middle East & Africa
- 8.3. Global Meningococcal Vaccines Market Attractiveness, by Country/Region
9. North America Meningococcal Vaccines Market Analysis and Forecast
- 9.1. Introduction
- 9.2. North America Meningococcal Vaccines Market Value Forecast, by Type, 2021-2031
- 9.2.1. Polysaccharide
- 9.2.1.1. Menomune
- 9.2.1.2. Mencevax
- 9.2.1.3. NmVac4
- 9.2.1.4. Others
- 9.2.2. Conjugate Vaccines
- 9.2.2.1. Menactra
- 9.2.2.2. Menveo
- 9.2.2.3. NeisVac-C
- 9.2.2.4. Nimenrix
- 9.2.2.5. Others
- 9.2.3. Combination Vaccines
- 9.2.3.1. MenHibrix
- 9.2.3.2. Menitorix
- 9.2.4. Men B Vaccines
- 9.2.4.1. Bexsero
- 9.2.4.2. Trumenba
- 9.3. North America Meningococcal Vaccines Market Value Forecast, by End-user, 2021-2031
- 9.3.1. Retail Pharmacies
- 9.3.2. Hospital Pharmacies
- 9.3.3. Others (online pharmacies, drug stores)
- 9.4. North America Meningococcal Vaccines Market Value Forecast, by Country, 2021-2031
- 9.4.1. U.S.
- 9.4.2. Canada
- 9.5. North America Meningococcal Vaccines Market Attractiveness Analysis
- 9.5.1. By Type
- 9.5.2. By End-user
- 9.5.3. By Country
10. Europe Meningococcal Vaccines Market Analysis and Forecast
- 10.1. Introduction
- 10.2. Europe Meningococcal Vaccines Market Value Forecast, by Type, 2021-2031
- 10.2.1. Polysaccharide
- 10.2.1.1. Menomune
- 10.2.1.2. Mencevax
- 10.2.1.3. NmVac4
- 10.2.1.4. Others
- 10.2.2. Conjugate Vaccines
- 10.2.2.1. Menactra
- 10.2.2.2. Menveo
- 10.2.2.3. NeisVac-C
- 10.2.2.4. Nimenrix
- 10.2.2.5. Others
- 10.2.3. Combination Vaccines
- 10.2.3.1. MenHibrix
- 10.2.3.2. Menitorix
- 10.2.4. Men B Vaccines
- 10.2.4.1. Bexsero
- 10.2.4.2. Trumenba
- 10.3. Europe Meningococcal Vaccines Market Value Forecast, by End-user, 2021-2031
- 10.3.1. Retail Pharmacies
- 10.3.2. Hospital Pharmacies
- 10.3.3. Others (online pharmacies, drug stores)
- 10.4. Europe Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021-2031
- 10.4.1. Germany
- 10.4.2. U.K.
- 10.4.3. France
- 10.4.4. Italy
- 10.4.5. Spain
- 10.4.6. Rest of Europe
- 10.5. Europe Meningococcal Vaccines Market Attractiveness Analysis
- 10.5.1. By Type
- 10.5.2. By End-user
- 10.5.3. By Country/Sub-region
11. Asia Pacific Meningococcal Vaccines Market Analysis and Forecast
- 11.1. Introduction
- 11.2. Asia Pacific Meningococcal Vaccines Market Value Forecast, by Type, 2021-2031
- 11.2.1. Polysaccharide
- 11.2.1.1. Menomune
- 11.2.1.2. Mencevax
- 11.2.1.3. NmVac4
- 11.2.1.4. Others
- 11.2.2. Conjugate Vaccines
- 11.2.2.1. Menactra
- 11.2.2.2. Menveo
- 11.2.2.3. NeisVac-C
- 11.2.2.4. Nimenrix
- 11.2.2.5. Others
- 11.2.3. Combination Vaccines
- 11.2.3.1. MenHibrix
- 11.2.3.2. Menitorix
- 11.2.4. Men B Vaccines
- 11.2.4.1. Bexsero
- 11.2.4.2. Trumenba
- 11.3. Asia Pacific Meningococcal Vaccines Market Value Forecast, by End-user, 2021-2031
- 11.3.1. Retail Pharmacies
- 11.3.2. Hospital Pharmacies
- 11.3.3. Others (online pharmacies, drug stores)
- 11.4. Asia Pacific Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021-2031
- 11.4.1. China
- 11.4.2. Japan
- 11.4.3. India
- 11.4.4. Australia & New Zealand
- 11.4.5. Rest of Asia Pacific
- 11.5. Asia Pacific Meningococcal Vaccines Market Attractiveness Analysis
- 11.5.1. By Type
- 11.5.2. By End-user
- 11.5.3. By Country/Sub-region
12. Latin America Meningococcal Vaccines Market Analysis and Forecast
- 12.1. Introduction
- 12.2. Latin America Meningococcal Vaccines Market Value Forecast, by Type, 2021-2031
- 12.2.1. Polysaccharide
- 12.2.1.1. Menomune
- 12.2.1.2. Mencevax
- 12.2.1.3. NmVac4
- 12.2.1.4. Others
- 12.2.2. Conjugate Vaccines
- 12.2.2.1. Menactra
- 12.2.2.2. Menveo
- 12.2.2.3. NeisVac-C
- 12.2.2.4. Nimenrix
- 12.2.2.5. Others
- 12.2.3. Combination Vaccines
- 12.2.3.1. MenHibrix
- 12.2.3.2. Menitorix
- 12.2.4. Men B Vaccines
- 12.2.4.1. Bexsero
- 12.2.4.2. Trumenba
- 12.3. Latin America Meningococcal Vaccines Market Value Forecast, by End-user, 2021-2031
- 12.3.1. Retail Pharmacies
- 12.3.2. Hospital Pharmacies
- 12.3.3. Others (online pharmacies, drug stores)
- 12.4. Latin America Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021-2031
- 12.4.1. Brazil
- 12.4.2. Mexico
- 12.4.3. Rest of Latin America
- 12.5. Latin America Meningococcal Vaccines Market Attractiveness Analysis
- 12.5.1. By Type
- 12.5.2. By End-user
- 12.5.3. By Country/Sub-region
13. Middle East & Africa Meningococcal Vaccines Market Analysis and Forecast
- 13.1. Introduction
- 13.2. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by Type, 2021-2031
- 13.2.1. Polysaccharide
- 13.2.1.1. Menomune
- 13.2.1.2. Mencevax
- 13.2.1.3. NmVac4
- 13.2.1.4. Others
- 13.2.2. Conjugate Vaccines
- 13.2.2.1. Menactra
- 13.2.2.2. Menveo
- 13.2.2.3. NeisVac-C
- 13.2.2.4. Nimenrix
- 13.2.2.5. Others
- 13.2.3. Combination Vaccines
- 13.2.3.1. MenHibrix
- 13.2.3.2. Menitorix
- 13.2.4. Men B Vaccines
- 13.2.4.1. Bexsero
- 13.2.4.2. Trumenba
- 13.3. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by End-user, 2021-2031
- 13.3.1. Retail Pharmacies
- 13.3.2. Hospital Pharmacies
- 13.3.3. Others (online pharmacies, drug stores)
- 13.4. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021-2031
- 13.4.1. GCC Countries
- 13.4.2. South Africa
- 13.4.3. Rest of Middle East & Africa
- 13.5. Middle East & Africa Meningococcal Vaccines Market Attractiveness Analysis
- 13.5.1. By Type
- 13.5.2. By End-user
- 13.5.3. By Country/Sub-region
14. Competition Landscape
- 14.1. Market Player - Competition Matrix (by tier and size of companies)
- 14.2. Market Share Analysis, by Company, 2021
- 14.3. Company Profiles
- 14.3.1. Sanofi SA
- 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.1.2. Product Portfolio
- 14.3.1.3. SWOT Analysis
- 14.3.1.4. Strategic Overview
- 14.3.2. Novartis International
- 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.2.2. Product Portfolio
- 14.3.2.3. SWOT Analysis
- 14.3.2.4. Strategic Overview
- 14.3.3. GlaxoSmithKline plc
- 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.3.2. Product Portfolio
- 14.3.3.3. SWOT Analysis
- 14.3.3.4. Strategic Overview
- 14.3.4. Pfizer Inc.
- 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.4.2. Product Portfolio
- 14.3.4.3. SWOT Analysis
- 14.3.4.4. Strategic Overview
- 14.3.5. Nuron Biotech.
- 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.5.2. Product Portfolio
- 14.3.5.3. SWOT Analysis
- 14.3.5.4. Strategic Overview
- 14.3.6. JN-International Medical Corporation.
- 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.6.2. Product Portfolio
- 14.3.6.3. SWOT Analysis
- 14.3.6.4. Strategic Overview
- 14.3.7. Serum Institute of India Ltd
- 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.7.2. Product Portfolio
- 14.3.7.3. SWOT Analysis
- 14.3.7.4. Strategic Overview
- 14.3.8. Baxter International
- 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.8.2. Product Portfolio
- 14.3.8.3. SWOT Analysis
- 14.3.8.4. Strategic Overview